Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{185038,
        author = {Dr Sahil Arora and Dr VIMALA AJITH},
        title = {Integrative Approach to Cosmetic-Induced Contact Dermatitis Comparative Insights on Clobetasol and Kinsukadi Taila},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {5},
        pages = {126-131},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=185038},
        abstract = {Background: Cosmetic-induced contact dermatitis (CICD) is an increasingly prevalent skin disorder caused by allergens and irritants present in cosmetic products. It manifests as erythema, pruritus, scaling, vesiculation, and post-inflammatory pigmentation, significantly impacting quality of life. Conventional dermatology relies on topical corticosteroids such as clobetasol propionate for rapid anti-inflammatory control. However, prolonged or inappropriate use is associated with adverse effects including skin atrophy, telangiectasia, tachyphylaxis, and steroid-induced dermatitis. Objective: This review aims to provide comparative insights into clobetasol and Kinshukadi Taila, an Ayurvedic polyherbal formulation traditionally used for inflammatory and pigmentary skin conditions, and to propose an integrative approach to CICD management. Methods: Literature from modern dermatology and Ayurveda was reviewed, including clinical trials, systematic reviews, case series, and pharmacological studies. Comparative evaluation focused on mechanisms of action, therapeutic efficacy, safety profile, and clinical applicability of both therapies. Results: Clobetasol propionate is effective in rapidly controlling acute flares of CICD and is strongly supported by clinical evidence and guidelines. Its limitations include risk of adverse events and the necessity for physician-supervised, short-term use. Kinshukadi Taila, composed of herbs such as Butea monosperma, Rubia cordifolia, Curcuma longa, and Tinospora cordifolia, has demonstrated anti-inflammatory, antioxidant, and complexion-enhancing properties in traditional use and small-scale studies. Although evidence is promising, rigorous randomized controlled trials are lacking. Kinshukadi Taila appears safer for longer-term use but may cause allergic reactions in sensitive individuals. Conclusion: An integrative model combining the rapid, short-term efficacy of clobetasol with the safer, restorative potential of Kinshukadi Taila offers a pragmatic approach to CICD management. Acute inflammation may be best managed with supervised corticosteroid therapy, while Ayurvedic oil formulations may support skin barrier repair, reduce pigmentation sequelae, and minimize steroid dependence. Further large-scale, standardized trials are required to validate the efficacy and safety of Kinshukadi Taila in comparison with conventional corticosteroids.},
        keywords = {cosmetic-induced contact dermatitis; clobetasol propionate; Kinshukadi Taila; topical corticosteroid; Ayurveda; integrative dermatology},
        month = {September},
        }